An envelope domain III–based chimeric antigen produced in Pichia pastoris elicits neutralizing antibodies against all four dengue virus serotypes

Etemad, Behzad ; Batra, Gaurav ; Raut, Rajendra ; Dahiya, Satinder ; Khanam, Saima ; Swaminathan, Sathyamangalam ; Khanna, Navin (2008) An envelope domain III–based chimeric antigen produced in Pichia pastoris elicits neutralizing antibodies against all four dengue virus serotypes The American Journal of Tropical Medicine and Hygiene, 79 (3). pp. 353-363. ISSN 0002-9637

Full text not available from this repository.

Official URL: http://www.ajtmh.org/content/journals/10.4269/ajtm...

Related URL: http://dx.doi.org/10.4269/ajtmh.2008.79.353

Abstract

There is currently no vaccine to prevent dengue (DEN) virus infection, which is caused by any one of four closely related serotypes, DEN-1, DEN-2, DEN-3 or DEN-4. A DEN vaccine must be tetravalent, because immunity to a single serotype does not offer cross-protection against the other serotypes. We have developed a novel tetravalent chimeric protein by fusing the receptor-binding envelope domain III (EDIII) of the four DEN virus serotypes. This protein was expressed in the yeast, Pichia pastoris and purified to near homogeneity in high yields. Antibodies induced in mice by the tetravalent protein, formulated in different adjuvants, neutralized the infectivity of all four serotypes. This, coupled with the high expression potential of the P. pastoris system and easy one-step purification, makes the EDIII-based recombinant protein a potentially promising candidate for the development of a safe, efficacious, and inexpensive, tetravalent DEN vaccine.

Item Type:Article
Source:Copyright of this article belongs to American Society of Tropical Medicine and Hygiene.
ID Code:109079
Deposited On:09 Mar 2018 12:12
Last Modified:09 Mar 2018 12:12

Repository Staff Only: item control page